Is taltz a biologic?

Is taltz a biologic?

Yes, Taltz (ixekizumab) is a biologic drug. It is a monoclonal antibody produced using recombinant DNA technology in living cells rather than through chemical synthesis.

Why is Taltz classified as a biologic?

Biologics are large, complex molecules derived from living organisms. Taltz targets interleukin-17A (IL-17A), a protein involved in inflammation. Because it is made in Chinese hamster ovary cells and requires precise manufacturing controls, it falls under the biologic category regulated by the FDA's Center for Biologics Evaluation and Research.

How is Taltz administered?

Taltz is given by subcutaneous injection, typically every two weeks for the first few doses, then monthly. Patients can self-inject after training, or receive it in a clinic setting.

How does Taltz compare to other IL-17 inhibitors like Cosentyx?

Both Taltz and Cosentyx (secukinumab) block IL-17 signaling. Taltz is selective for IL-17A only, while Cosentyx blocks IL-17A, IL-17F, and IL-17A/F heterodimers. Head-to-head data show similar efficacy for plaque psoriasis, with slight differences in speed of onset and dosing schedules.

When does Taltz's patent expire?

The primary U.S. composition-of-matter patent for ixekizumab expires in 2026, with additional patents extending protection into the early 2030s. Biosimilar development is already underway, though launch timing will depend on patent litigation outcomes.

Can biosimilars enter the market before patent expiry?

Current law allows biosimilar applicants to file under the Biologics Price Competition and Innovation Act once data exclusivity ends in 2026. Actual market entry hinges on the resolution of ongoing or potential patent disputes.

Who makes Taltz?

Eli Lilly manufactures and markets Taltz. The drug is produced at Lilly's facilities approved by the FDA for biologic manufacturing.

What side effects are patients asking about?

Common questions focus on injection-site reactions, upper respiratory infections, and rare cases of inflammatory bowel disease flares. Long-term safety data from extension studies continue to be monitored through post-marketing surveillance.

Where can I find more details on Taltz patents and exclusivity?

DrugPatentWatch.com tracks U.S. and international patents, regulatory exclusivities, and biosimilar pipelines for Taltz and other biologics.